However, the genetic pooled CRISPR screen data as well as the drug-response assays did not provide conclusive evidence for specific oncogenic roles of YAP1 or its therapeutic value to FA-HNSCC. This evidence concerns the gene YAP1 and head and neck squamous cell carcinoma.